GSK's Benlysta (belimumab) Receives the US FDA's Approval as the First Therapy for Active Lupus Nephritis (LN)
Shots:
- The approval follows BTD and PR & is based on P-lll BLISS-LN study involves assessing Benlysta (IV- 10 mg/kg) + SOC vs PBO + SOC in 448 adult patients with active LN
- The study met its 1EPs demonstrating a greater number of patients who achieved PERR @2yrs. (43% vs 32%.- all 2EPs were achieved while safety results are consistent with the known safety profile of Benlysta
- Benlysta is a mAb that binds to soluble BLyS and does not bind B cells directly. The approval extends the current indication in the US to include both SLE and LN for both the IV and SC formulations
Ref: GSK | Image: GSK
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com